Saturday, August 19, 2017 4:08:44 PM
It is all it is, words on paper, these flexible attributes on the preliminary are made to benefit management and placebo investors.
This will change to Mr. Soons advantage, Mr Soon wants CYTR as part of his company portfolio, He bought a stake on CYTR already and payed a 92% premium on the share value as stated on (7/28/17 PR)
He believes the drug he bought on paper jas tremendous potential.
He just wants his money now,
New manahement will make the stock sky rocket
without an RS
Wise
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM